Comparative Pharmacology
Head-to-head clinical analysis: ENOVID versus TRI SPRINTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID versus TRI SPRINTEC.
ENOVID vs TRI-SPRINTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (LH, FSH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases viscosity of cervical mucus and alters endometrial lining to impair implantation.
Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation, and increases viscosity of cervical mucus to inhibit sperm penetration.
Oral, 5 mg daily for 20 days starting on day 5 of menstrual cycle for ovulation inhibition; for endometriosis, 5 mg daily for 15 days increasing to 10 mg daily if breakthrough bleeding occurs.
One tablet (0.035 mg ethinyl estradiol / 0.250 mg norgestimate) orally once daily for 21 days, followed by 7 days of placebo tablets. Repeat cycle.
None Documented
None Documented
Norethynodrel: 5-12 hours; mestranol: 7-20 hours. Terminal half-life of ethinyl estradiol from mestranol conversion: 10-30 hours. Clinical context: steady-state achieved after 3-5 half-lives (3-5 days).
Norelgestromin: 28 hours; Ethinyl estradiol: 17 hours. Steady-state achieved within 7 days.
Renal (30-50% as metabolites, <5% unchanged) and fecal (40-60% via bile, mostly as glucuronide conjugates).
Renal: 50% (metabolites); Fecal: 35% (eliminated in bile); unchanged drug <1%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive